2018 Adult Asthma Data: Prevalence Tables and Maps

Table C1
Adult* Self-Reported Current Asthma Prevalence and Number by State or Territory, BRFSS 2018
State Sample Size§ Prevalence (percent) Standard Error class=”text-center”95% CI (percent) ||
||
||
Weighted Number 95% CI (Weighted Number)
U.S. Total** 427,671 9.2 0.09 (9.1–9.4) || 23,420,806 (22,967,727–23,873,886)
AL 6,542 10.5 0.52 (9.4–11.5) || 394,634 (354,877–434,392)
AK 2,731 9.2 0.78 (7.7–10.7) || 50,685 (42,146–59,225)
AZ 8,026 10.0 0.54 (8.9–11.1) || 545,104 (486,686–603,521)
AR 5,322 9.8 0.63 (8.6–11.1) || 225,853 (197,027–254,679)
CA 11,864 8.5 0.34 (7.8–9.2) || 2,607,598 (2,400,046–2,815,150)
CO 8,805 9.1 0.37 (8.4–9.8) || 399,357 (367,251–431,463)
CT 10,617 10.3 0.40 (9.5–11.1) || 290,278 (267,645–312,911)
DE 5,194 10.1 0.62 (8.9–11.3) || 77,035 (67,543–86,527)
DC 4,356 11.6 0.70 (10.2–13.0) || 66,441 (58,335–74,548)
FL 15,153 8.7 0.47 (7.8–9.7) || 1,495,632 (1,333,615–1,657,649)
GA 9,217 8.9 0.38 (8.2–9.7) || 714,569 (654,623–774,515)
HI 7,874 9.3 0.46 (8.4–10.2) || 104,368 (94,081–114,655)
ID 3,653 8.6 0.63 (7.4–9.9) || 111,954 (95,797–128,112)
IL 5,275 8.7 0.47 (7.8–9.7) || 860,007 (768,316–951,699)
IN 7,543 10.0 0.45 (9.1–10.9) || 509,651 (464,406–554,897)
IA 9,072 7.9 0.33 (7.2–8.6) || 190,960 (174,914–207,006)
KS 10,735 9.8 0.38 (9.1–10.5) || 214,698 (198,174–231,221)
KY 8,482 11.5 0.59 (10.3–12.6) || 395,345 (354,171–436,519)
LA 5,080 8.9 0.64 (7.6–10.2) || 316,423 (269,655–363,191)
ME 10,861 12.3 0.57 (11.1–13.4) || 132,126 (119,634–144,619)
MD 17,396 9.3 0.36 (8.6–10.1) || 439,909 (405,249–474,569)
MA 6,609 10.2 0.49 (9.2–11.1) || 558,435 (504,116–612,753)
MI 10,245 11.2 0.41 (10.4–12.0) || 872,519 (808,048–936,991)
MN 16,904 8.3 0.26 (7.8–8.8) || 357,232 (334,517–379,947)
MS 5,802 9.7 0.51 (8.7–10.7) || 218,223 (195,564–240,881)
MO 6,187 9.4 0.54 (8.4–10.5) || 444,334 (393,901–494,767)
MT 5,153 10.0 0.58 (8.8–11.1) || 82,660 (73,058–92,262)
NE 14,559 8.9 0.38 (8.1–9.6) || 128,793 (117,804–139,782)
NV 3,195 8.0 0.76 (6.5–9.5) || 186,787 (151,054–222,521)
NH 5,693 11.8 0.65 (10.5–13.1) || 128,307 (113,886–142,728)
NJ 3,072 8.4 0.72 (7.0–9.8) || 593,242 (493,842–692,641)
NM 6,669 9.9 0.51 (8.9–10.9) || 157,177 (141,187–173,168)
NY 35,411 10.1 0.30 (9.6–10.7) || 1,578,011 (1,485,773–1,670,249)
NC 4,708 9.4 0.57 (8.2–10.5) || 757,790 (664,634–850,947)
ND 5,580 8.2 0.54 (7.1–9.2) || 46,996 (40,818–53,174)
OH 12,675 9.4 0.40 (8.7–10.2) || 854,186 (781,852–926,520)
OK 5,222 10.3 0.55 (9.2–11.4) || 307,581 (274,616–340,546)
OR 5,890 11.6 0.53 (10.6–12.7) || 383,340 (347,824–418,856)
PA 6,167 10.0 0.49 (9.1–11.0) || 1,012,588 (914,077–1,111,099)
RI 5,559 11.9 0.64 (10.7–13.2) || 101,251 (90,363–112,139)
SC 10,785 9.1 0.40 (8.3–9.8) || 360,353 (328,559–392,147)
SD 7,060 7.9 0.60 (6.7–9.0) || 51,652 (43,787–59,518)
TN 5,121 9.8 0.57 (8.7–10.9) || 513,084 (454,259–571,908)
TX 11,118 7.4 0.47 (6.5–8.3) || 1,572,815 (1,374,829–1,770,800)
UT 10,472 9.3 0.37 (8.6–10.0) || 206,360 (190,107–222,612)
VT 6,490 12.0 0.61 (10.8–13.2) || 60,216 (54,044–66,388)
VA 10,247 8.5 0.39 (7.8–9.3) || 563,510 (512,877–614,144)
WA 12,991 9.6 0.35 (8.9–10.3) || 558,951 (518,658–599,244)
WV 4,873 12.3 0.59 (11.1–13.4) || 175,368 (158,492–192,244)
WI 4,973 9.0 0.56 (7.9–10.1) || 408,318 (358,281–458,354)
WY 4,443 8.7 0.54 (7.6–9.7) || 38,099 (33,385–42,813)
Territories
GU 1,634 5.0 0.67 (3.6–6.3) || 5,272 (3,884–6,660)
PR 4,833 11.1 0.56 (10.0–12.2) || 303,623 (273,026–334,221)

Notes:
*Aged 18+ years
**U.S. Total includes 50 states plus the District of Columbia and excludes the three territories.
CI denotes confidence interval.
§Sample size is the number of respondents answered current asthma question

If values for the standard error and the 95% confidence interval are not provided, the normal approximation to the binomial distribution does not apply due to small sample size.

When the Sample Size is less than 50, estimates are not precise and should be interpreted with caution.

Asthma and Community Health Branch, National Center for Environmental Health
Centers for Disease Control and Prevention

Page last reviewed: March 26, 2020